SL Science Holding Ltd (SLBT), a biomedical company, reported financial results for the full year 2025, reflecting a 35% decline in revenue compared to the prior year.
Company Profile
SL Science Holding develops innovative cellular and gene therapies. They also manufacture skin- and scalp-care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series.
The company operates in three segments: Exosome products, CD-19 Armed-T products and GDT Cell Therapy products, with its therapeutic programs currently in preclinical development.
Full Year 2025 Results
For the full year 2025, net loss expanded to $3.82 million from $1.19 million a year ago.
Net revenue of the company slipped by 35% to $2.19 million from $3.36 million in the prior year. The decline was primarily driven by the company's transition in Taiwan from direct retail sales of exosome concentrate products to a wholesale distribution model via corporate distributors.
The net revenue represented only the sales of Exosome products.
As of December 31, 2025, SL Science's restricted and unrestricted cash balances were approximately $1.26 million.
Milestones Ahead
According to the company, GLP toxicology studies are expected to begin following the delivery of required manufacturing reagents in the first quarter of 2027, supporting a targeted IND filing in the third quarter of 2027.
SLBT closed Thursday's trade at $5.79. SLBT is currently down 12.54% at $5.09.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.